| Description: |
GW6604 is a potent and selective ALK-5 inhibitor with potent anticancer activity. GW6604 is also a TGF-beta signaling pathway inhibitor. In vitro, GW6604 inhibited autophosphorylation of ALK5 with an IC(50) of 140 nM and in a cellular assay inhibited TGF-beta-induced transcription of PAI-1 (IC(50): 500 nM). In vivo, GW6604 (40 mg kg(-1) p.o.) increased liver regeneration in TGF-beta-overexpressing mice, which had undergone partial hepatectomy. In an acute model of liver disease, GW6604 reduced by 80% the expression of collagen IA1. Inhibition of ALK5 could be an attractive new approach to treatment of liver fibrotic diseases by both preventing matrix deposition and promoting hepatocyte regeneration. (Br J Pharmacol. 2005 May;145(2):166-77.). (Last updated: 2/9/2015) For the detailed information of GW6604, the solubility of GW6604 in water, the solubility of GW6604 in DMSO, the solubility of GW6604 in PBS buffer, the animal experiment (test) of GW6604, the cell expriment (test) of GW6604, the in vivo, in vitro and clinical trial test of GW6604, the EC50, IC50,and affinity,of GW6604, Please contact DC Chemicals. |
